Multiparametric MRI as a Non-Invasive Biomarker of the Tumor Microenviroment

This study is looking at how an imaging test could help doctors understand if a patient with early breast cancer will respond to drugs that use the patient's immune system to fight cancer.

Inclusion Criteria: Women and men at least 18 years of age. * Have a new diagnosis of invasive breast cancer with clinical stage I - III disease or regional stage IV with metastasis to the supraclavicular nodes only * Hormone receptor negative (estrogen-receptor \< 5% and/or progesterone-receptor \< 5%) * Human epidermal growth factor receptor 2 (HER2) negative by immunohistochemistry or fluorescence in situ hybridization (FISH) * Enrollment in a neoadjuvant clinical trial that includes the evaluation of immunotherapy as a part of the regimen; patient must be randomized to a treatment arm (including the control arm) prior to enrolling in this study * Planning to undergo surgical resection and subsequent adjuvant therapy as per the treatment clinical trial or the clinical provider * Have tissue available for additional correlative studies OR planned to undergo an additional pre-treatment biopsy for additional tissue acquisition as per provider or the treatment clinical trial * Be a candidate for MRI imaging. * Be willing to comply with scheduled visits required for the trial. * Ability to understand and the willingness to sign a written informed consent document. Exclusion Criteria: Systemic or locoregional treatment for the current episode of breast cancer prior to baseline breast MRI. * Poor visualization of the tumor on the initial breast MRI (investigator discretion) * Pregnant or nursing.